Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 7/20 | 0.45 |
| ▸ | MME | P08473 | 1/20 | 0.45 |
| ▸ | CPA1 | P15085 | 1/20 | 0.45 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.45 |
| ▸ | MASP2 | O00187 | 3/20 | 0.41 |
| ▸ | F2 | P00734 | 2/20 | 0.40 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.40 |
| ▸ | CHRND | Q07001 | 5/20 | 0.39 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.39 |
| ▸ | CHRNG | P07510 | 1/20 | 0.39 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.39 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1431636 | 0.91 | MME (0.43) | ACEMMECPA1ACE2MASP2 | |
| SCHEMBL1431649 | 0.91 | HTT (0.43) | MASP2KLKB1 | |
| SCHEMBL1432883 | 0.90 | FURIN (0.40) | ACEMMECPA1ACE2MASP2 | |
| SCHEMBL1431962 | 0.88 | ACE (0.47) | ACEMMECPA1ACE2MASP2 | |
| SCHEMBL1432300 | 0.88 | MASP2 (0.40) | ACEMMECPA1ACE2MASP2 | |
| SCHEMBL1432562 | 0.87 | MME (0.43) | ACEMMECPA1ACE2MASP2 | |
| SCHEMBL1432022 | 0.87 | MME (0.43) | ACEMMECPA1ACE2MASP2 | |
| SCHEMBL1434219 | 0.87 | KLKB1 (0.42) | MASP2KLKB1 | |
| SCHEMBL1431722 | 0.87 | MASP2 (0.40) | MASP2KLKB1 | |
| SCHEMBL1432034 | 0.86 | CTSB (0.43) | MASP2KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2300428-A1 | AMINOPYRIDINE DERIVATIVES | Vantia Limited (GB) | 2011-03-30 | — | — | EP | disclosed |